Abstract

Background

The effects of low concentration of sevoflurane on right ventricular (RV) function and intracellular calcium in the setting of pulmonary arterial hypertension (PAH) have not been investigated clearly. We aim to study these effects and associated signaling pathways in rats with PAH.

Methods

Hemodynamics were assessed with or without sevoflurane inhalation in established PAH rats. We analysis the classic RV function parameters and RV-PA coupling efficiency using steady-state PV loop recordings. The protein levels of SERCA2, PLB and p-PLB expression was analyzed by western blot to assess their relevance in PAH.

Results

Rats with PAH presented with RV hypertrophy and increased pulmonary arterial pressure. The values of Ea, R/L ratio, ESP, SW, PRSW, +dP/dtmax and the slope of the dP/dtmax-EDV relationship increased significantly in PAH rats ($P<0.05$). Sevoflurane induced a concentration-dependent decrease of systemic and pulmonary blood pressure, HR, RV contractility, and increased the R/L ratio in both groups. Sevoflurane reduced the expression of SERCA2 and increased the expression of PLB in both groups. Interestingly, sevoflurane only reduced the p-PLB/PLB ratio in PAH rats, not in normal rats.

Conclusions

Rats with chronic, stable pulmonary hypertension tolerate low concentrations of sevoflurane inhalation as well as normal rats do. It may be related to the modulation of the SERCA2-PLB signaling pathway.
Introduction

Pulmonary arterial hypertension (PAH) is characterized by chronically increased intravascular pressure and resistance, which results in right ventricular (RV) hypertrophy, dilatation, right heart failure, and ultimately death[1–3]. PAH is a major risk factor for mortality in patients undergoing surgery. In cardiac surgery, PAH patients exhibit higher mortality than patients without PAH[4, 5]. In non-cardiac surgery, PAH is associated with worse perioperative outcomes. In-hospital mortality of severe PAH patients is up to 10%. [6, 7] The choice of anesthetic agent is crucial in the perioperative management of patients with PAH. Midazolam, fentanyl, neuromuscular blocking agents with minimal hemodynamic effects and a small dose of propofol has been recommended for induction of anesthesia in pediatric PAH patients[8, 9]. Sevoflurane is a widely used volatile agent that affords cardioprotection and neuroprotection [10,11]. However, sevoflurane can produce dose-dependent decreases of both pulmonary and systemic pressures.[12, 13]. Little is known about the effects of sevoflurane on RV function in patients with PAH.

The monocrotaline (MCT)-induced PAH in rats is the most commonly used animal model. A single injection of MCT can result in injury of the vascular endothelium, pulmonary hypertension, RV hypertrophy and failure within 3 to 4 weeks [14–16].

Growing evidence implicates that downregulation of sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) plays an important role in PAH. Alterations in Ca2+ homeostasis not only stimulate pulmonary vascular proliferation but also impact RV myocardial contractility [14, 17]. The activation of SERCA2a depends on the phosphorylation of phospholamban (PLB) at Ser16 and at Thr17, allowing for increased Ca2+ pumping into the sarcoplasmic reticulum[18]. It is unclear whether the SERCA2a–PLB pathway is important to RV function in PAH, especially with sevoflurane administration.

We hypothesized that sevoflurane inhalation would affect RV function and the SERCA2-PLB pathway is affected in MCT induced PAH model. Primary end points are RV end-systolic elastance (Ees), preload recruitable stroke work (PRSW), and the slope of the relation of the maximum derivative of RV pressure (dP/dt_max) to end-diastolic volume (EDV), effective arterial elastance (Ea), and RV-PA coupling efficiency assessed by Ees/Ea ratio. [19] SERCA2, PLB, p-PLB levels are compared after sevoflurane inhalation between normal and PAH animals.

Methods

Animals

All experiments received prior approval by the Ethics Committee for Animal Research of Xiangya Hospital (201303311). All surgery was performed under proper anesthesia, and all efforts were made to minimize suffering. Adult male Sprague-Dawley rats (SPF grade, Xiangya Medical College, Changsha, HN, China) weighing between 250 and 280 g were fed with the same bacteria-free diet and water and housed at 23°C on a 12 h/12 h dark/light cycle.

Modeling and grouping

Rats were treated with solvent of 1% monocrotaline (Crotaline C2401, Sigma-Aldrich, Buchs, Switzerland) by a single intraperitoneal injection at a dose of 60 mg/kg administered 28 days before the experiment. Schematic diagram depicting the experimental protocols used in the sevoflurane inhalation experiments was shown in S1 Fig. Monocrotaline was dissolved in ethanol and diluted with normal saline. After injection of MCT or NS, the rats received high-quality care by laboratory animal technicians. The professional staff and members of our research
team inspected the animals every day and disposed in time. Occasionally the rats were very sick and stopped eating before 28th day, then they were given early euthanasia. If the rat was severely sick and stopped eating, the protocol of the early euthanasia was taken. Cervical dislocation was done under ketamine anesthesia. The rats with or without monocrotaline injection were divided randomly into groups with or without sevoflurane inhalation before instrumentation. Therefore, rats were divided into 4 groups: group NS (n = 8), group MCT (n = 8), group NS-sevo (n = 12), and group MCT-sevo (n = 13). All observers/recorders were blinded to animal assignments.

Surgical preparation

The rats were anesthetized with ketamine (60 mg/kg) by intraperitoneal injection and placed on an electrical heating pad to maintain body temperature at 37°C to 38°C. Then, the rats were intubated by tracheotomy with a 16-gauge catheter. The left femoral artery and the right femoral vein were catheterized with 24-gauge catheters to record systemic arterial pressure and to infuse lactated Ringer’s solution at 10 ml kg⁻¹ h⁻¹ throughout the experiment. Before opening the chest, 1 mcg/kg sufentanil (Renfu, Yichang, Hubei, CHN) were given intravenously and then infuse sufentanil 1 mcg kg⁻¹ h⁻¹ to ensure the maintenance of anesthesia. The rats were mechanically ventilated (Model 683, Harvard Apparatus, USA) initially with 100% oxygen at a tidal volume of 5 ml/kg and a respiratory rate of 70–80 min⁻¹. A positive end-expiratory pressure of 3 cmH₂O was used to prevent atelectasis. After midline sternotomy, the pulmonary artery and right ventricle were catheterized and parameters measured.

Experimental protocol

A PE catheter was inserted into the pulmonary artery to monitor pulmonary arterial pressure. Then, the right ventricle was catheterized with a 1.9 F conductance pressure-volume (PV) catheter (Millar Instruments Inc., USA) along the long axis. The correct position was determined by online visualization of the PV loops. Right ventricular function was determined by PV loops and was continuously monitored throughout the experimental procedure with a PowerLab system (ADInstruments, Australia) via a conductance PV catheter placed in the RV. During the procedure, right ventricular pressure and volume as well as steady-state and dynamic PV loops during occlusion of the IVC were continuously recorded. For each condition, data were obtained after a 5-second period while mechanical ventilation was suspended, followed by a transient reduction of RV preload through IVC occlusion (<5 sec), and approximately 10–20 cardiac cycles were selected and used for later analysis with LabChart analysis software (ADInstruments, Australia).

After 30 min of postoperative stabilization, rats in groups with sevoflurane inhalation were exposed to stepwise increasing doses (0.5%, 1.0%, and 1.5%) of sevoflurane, each dose for periods of 30 min (corresponding timing T1, T2, T3). We chose this dose because lower dose of sevoflurane is usually used for critical patients with PAH to avoid systemic hypotension in clinical settings [20]. Rats in the other groups received oxygen without sevoflurane and were maintained for the same times. Hemodynamic data and cardiac function parameters were collected before sevoflurane inhalation (baseline T0) and at each concentration after 30 min of equilibration. After animals were sacrificed by exsanguination, the organs were harvested for analysis.

Measurements of hemodynamic and RV cardiac function

Data were continuously recorded and stored for later analysis. For each baseline and experimental condition, at least 20 consecutive cardiac cycles were selected and used for analysis. From the systemic and pulmonary arterial pressure recordings, we derived standard hemodynamic
variables: HR, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean systemic arterial pressure (MAP), systolic pulmonary arterial pressure (sPAP), diastolic pulmonary arterial pressure (dPAP), R/L ratio.

From steady-state PV loop recordings, we derived the following classic RV function parameters: RV end-systolic pressure (ESP), RV end-diastolic pressure (EDP), RV end-systolic volume (ESV), RV end-diastolic volume (EDV), RV stroke volume (SV), RV cardiac output (CO), RV ejection fraction (EF), RV stroke work (SW), and Ea., assuming that the left ventricular CO equals the RV CO. RV contractility was quantified by three parameters: Ees (the slope of end-systolic pressure-volume relations), PRSW, and the slope of the dP/dtmax-EDV relation. These parameters are useful to evaluate RV contractile performance because they are load independent. Finally, RV-PA coupling efficiency was assessed using Ees/Ea.

Morphometric analysis

After sacrifice of the rats, the hearts were removed and frozen for 15 min at -20°C and then cut into transverse slices of 2 mm and photographed. The midventricular slice was used to estimate the ratio of right ventricular over left ventricular wall thickness using an image analysis program. The weight of RV free wall and left ventricle (LV) plus septum (S) were determined by reassembling the respective wall slices, and the weight ratio of RV to (LV+S) was used to estimate the degree of RV hypertrophy. The hearts and left lungs were removed and fixed in 4% paraformaldehyde and embedded in paraffin for histological analysis. The paraffin-embedded sections were processed for hematoxylin and eosin staining.

Western blot analysis

The samples of right ventricle were homogenized in RIPA Lysis Buffer containing 20 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin (20 ml/g tissue) and 1 mM phenylmethylsulfonyl fluoride (Wellbiology, China) containing PMSF(1Mm) and placed on ice for 30 min. The homogenates were centrifuged at 14,000 g for 30 min at 4°C to remove cell debris, and protein concentrations were measured with a BCA protein assay kit (Wellbiology, China). Proteins (20μg) were resolved by 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride (PVDF) membranes. After blocking with 5% non-fat milk in Tris-buffered saline-0.1% Tween 20 (TBST), membranes were immunoblotted overnight at 4°C with primary antibodies against SERCA2, PLB, p-PLB and Na-K-ATPase (1:1000; Cell Signaling Technology, USA), followed by incubation with the corresponding secondary HRP-conjugated antibody (1:4000; ComWin Biotech, China) at room temperature for 60 min. The immunoreactivity was detected by ECL (Thermo Scientific Pierce, USA) and exposed to X-ray film. The signal intensity was normalized to Na-K-ATPase expression.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 6 software (GraphPad, La Jolla, CA, USA). The distributions of the continuous variables were expressed as means ± SD. Morphometric data, baseline hemodynamic data between control and monocrotaline group were compared using a two-sample t-test. For hemodynamic and RV function data, repeated-measures ANOVA was used to evaluate difference over time. Comparisons were intra-group and between group, followed by post hoc LSD tests for multiple comparisons. Significance was assumed when the P value was less than 0.05.
Results
Morphometric analysis
The number of the rats who became very ill is less than 5% of total animals. There were two animals died prior to the experiment endpoints. The reason might be over dosage of anesthetics. Midventricular transverse sections of hearts from a normal rat (A) and a PAH rat (B) were shown in S2 Fig. RV wall thickness increased in the PAH rat. The body weights (BW) of rats at 28 days after MCT injection were significantly lower than those of control rats. The heart weight (HW) and RV weight of MCT-injected animals were significantly higher than those of control rats, whereas LV and septal (LV+S) weight was unaffected by MCT treatment. The RV to (LV+S) weight ratio increased significantly in MCT rats. The ratio of the right over left ventricle wall thickness was significantly different between normal rats and PAH rats, as was the ratio of heart weight over body weight. (Table 1) RV wall thickness increased significantly in MCT-treated rats and MCT-injected rats had markedly thickened pulmonary arterioles, narrowed lumens, hypertrophic endothelial cells, and a dense inflammatory infiltration around the arterioles. RV myocardial cells were hypertrophic and of inordinate arrangement after MCT treatment. (Fig 1).

Measurements of hemodynamic and RV cardiac function
In normal saline and MCT treated rats, HR and MAP decreased significantly and gradually in a concentration-dependent manner with sevoflurane administration (P<0.01). In MCT and MCT-sevo groups, mean pulmonary artery pressure significantly increased at T0 (P<0.05), whereas the R/L ratio of ventricular pressure was significantly higher than those of NS group and NS-sevo group at T0 (P<0.05). But mPAP didn’t change significantly after sevoflurane inhalation in any group. The R/L ratio of ventricular pressure increased significantly with sevoflurane administration in both of normal and PAH rats (P<0.05). (Fig 2)

At baseline (T0), MCT-sevo groups exhibited significantly increased ESP, Ea, R/L ratio, SW, PRSW, +dP/dtmax and the slope of the dP/dtmax -EDV relationship, slightly increased EDP, and slightly decreased CO, SV, and EF compared to normal rats. 1.5% sevoflurane administration did not change Ea, but the Ees/Ea ratio, Ees, PRSW, and dP/dtmax -EDV was decreased in both NS-sevo and MCT-sevo groups. Sevoflurane resulted in a decreased ejection capacity with reduced SV, CO, SW and EF, associated with increased ESV and EDV. But the values of ESP, SW, Ees, PRSW, and dP/dtmax -EDV, and Ea MCT-sevo group remained significantly higher than those in NS-sevo group after 1.5% sevoflurane inhalation. (Table 2). RV PV loop

Table 1. Cardiac morphometric data (n = 12).

| parameters     | Normal saline    | Monocrotaline    | P value |
|----------------|------------------|------------------|---------|
| BW, g          | 376.67 ± 27.41   | 316.75 ± 17.43   | 0.000   |
| HW, mg         | 896.7 ± 76.0     | 1045.7 ± 150.9   | 0.007   |
| RV weight, mg  | 183.0 ± 21.1     | 351.9 ± 79.2     | 0.000   |
| LV+S weight, mg| 671.1 ± 60.3     | 653.7 ± 87.6     | 0.577   |
| HW/BW, mg/g    | 0.24 ± 0.01      | 0.33 ± 0.04      | 0.000   |
| RV/(LV+S) weight| 0.27 ± 0.02     | 0.54 ± 0.10      | 0.000   |
| RV/LV wall thickness | 0.37 ± 0.03 | 0.55 ± 0.04 | 0.000   |

Values are expressed as means ± SD; n, number of rats; BW, body weight; HW, heart weight; RV, right ventricle; LV, left ventricle; S, septum. P values from Student’s unpaired t-test.

doi:10.1371/journal.pone.0154154.t001
demonstrated that sevoflurane reduced area, shifted loops rightward, decreased ESP, and decreased Ees in both normal and PAH rats (Fig 3).

**Western blot analysis.** Levels of SERCA2 and PLB were examined by Western blotting. Compared with the control group, the levels of SERCA2 were reduced, whereas PLB was increased in the MCT group ($P < 0.001$). The combined changes of the two proteins resulted in a decrease in SERCA2/PLB ratio in PAH rats ($P < 0.05$). After sevoflurane inhalation, the protein expression of SERCA2 was reduced, whereas that of PLB increased, resulting in a decreased SERCA2/PLB in all rats treated with sevoflurane (all $P < 0.05$). Interestingly, sevoflurane only diminished p-PLB/PLB ratio in PAH rats, not in normal rats ($P < 0.05$). (Fig 4)

**Discussion**

Our study was designed to examine the pulmonary hemodynamics and right ventricular function when low concentration of sevoflurane is administered to rats with or without pulmonary hypertension. We also investigated whether SERCA2-PLB signaling pathway is involved in this process. First, the pulmonary and systemic hemodynamic were similarly influenced by
Sevoflurane in rats with and without pulmonary hypertension. Second, sevoflurane affects RV contractility, and RV-PA coupling efficiency similarly in both normal and PAH rats. Finally, the SERCA2-PLB signaling pathway might play a role in PAH pathogenesis and in the effects of sevoflurane on PAH or non-PAH rats.

Previous studies in MCT-treated animals have shown a progressive development of PAH and RV hypertrophy consistent with our results.[21, 22] Sevoflurane produced a similar concentration-dependent depression of systemic hemodynamics in normal and PAH rats. There were no significant differences in baseline systemic hemodynamic between the normal rats and those with PAH. Heart rate and mean arterial pressure decreased similarly in the two types of rats during inhalation of sevoflurane from 0.5% to 1.5%. Previous studies showed that sevoflurane can produce a dose-dependent decrease in pulmonary and systemic hemodynamics and depression of RV function at doses above 1.0 minimum alveolar concentration (MAC)[13, 14]. In our study, the mean pulmonary artery pressure decreased and the R/L ratio of ventricular pressure increased after sevoflurane inhalation in both normal and PAH rats. These findings indicate that the pulmonary vascular tone of PAH is not more sensitive to sevoflurane than that of the normal pulmonary circulation.

RV function in both clinical and experimental studies is commonly assessed by RV EF or dP/dt max, but both parameters are highly dependent upon preload and afterload in addition to contractility[23, 24]. RV contractility is better evaluated by Ees, PRSW, and dP/dt max-EDV in PV loops analysis because the three variables are load independent[23, 25]. In the current study, MCT-treated rats exhibited intact RV contractility and RV CO and EF were maintained. Previous studies have shown that the right ventricle can adapt to PAH by an increase in contractility (homeometric autoregulation) and maintain CO[14, 26–28]. The value of Ea for the

---

![Fig 2. Values are expressed as means±SD. P values from repeated measures ANOVA; *, group NS compared with group NS-sevo, group MCT compared with MCT-sevo, P<0.05; **, group NS compared with group NS-sevo, group MCT compared with MCT-sevo, P<0.01; NS, group NS compared with group NS-sevo, group MCT compared with MCT-sevo, no significant. #, group NS compared with group MCT at T0, P<0.05, &, group NS-sevo compared with MCT-sevo at T0, P<0.05. HR, heart rate; MAP, mean systemic arterial pressure; mPAP, mean pulmonary arterial pressure; R/L ratio, ratio of systolic pulmonary arterial pressure over systolic blood pressure.](image)
Table 2. The parameters of right ventricular function.

| Parameter | Group    | T0       | T1       | T2       | T3       |
|-----------|----------|----------|----------|----------|----------|
| ESP (mmHg)| NS-sevo  | 31 ± 3   | 28 ± 4<sup>a</sup> | 25 ± 2<sup>ab</sup> | 24 ± 2<sup>abc</sup> |
|           | MCT-sevo | 49 ± 7<sup>d</sup> | 45 ± 8<sup>b</sup> | 43 ± 9<sup>ab</sup> | 41 ± 10<sup>ab</sup> |
| EDP (mmHg)| NS-sevo  | 2.24 ± 0.83 | 2.23 ± 1.09 | 2.08 ± 0.95 | 1.98 ± 0.99 |
|           | MCT-sevo | 3.03 ± 1.84 | 3.13 ± 1.48 | 2.40 ± 0.79 | 2.48 ± 0.94 |
| ESV (ul)  | NS-sevo  | 207±50 a  | 244±49 a  | 272±56<sup>ab</sup> | 298±58<sup>abc</sup> |
|           | MCT-sevo | 222±43 a  | 257±61<sup>a</sup> | 287±62<sup>ab</sup> | 307±70<sup>abc</sup> |
| EDV (ul)  | NS-sevo  | 251±56 a  | 290±61<sup>a</sup> | 307±61<sup>ab</sup> | 334±64<sup>abc</sup> |
|           | MCT-sevo | 279±49<sup>a</sup> | 313±70<sup>a</sup> | 333±70<sup>ab</sup> | 351±71<sup>abc</sup> |
| SV (ul)   | NS-sevo  | 64 ± 17   | 66 ± 20   | 58 ± 16<sup>ab</sup> | 52 ± 14<sup>abc</sup> |
|           | MCT-sevo | 68 ± 16   | 70 ± 16   | 65 ± 16<sup>ab</sup> | 59 ± 18<sup>abc</sup> |
| CO (ml/min)| NS-sevo | 27.63 ± 8.56 | 23.68 ± 6.85<sup>a</sup> | 19.25 ± 4.87<sup>ab</sup> | 16.33 ± 4.36<sup>abc</sup> |
|           | MCT-sevo | 28.56 ± 6.38 | 26.32 ± 5.17<sup>a</sup> | 22.95 ± 5.16<sup>ab</sup> | 19.80 ± 5.84<sup>abc</sup> |
| EF (%)    | NS-sevo  | 27.23 ± 4.99 | 23.96 ± 5.10<sup>a</sup> | 19.43 ± 3.30<sup>ab</sup> | 16.02 ± 2.30<sup>abc</sup> |
|           | MCT-sevo | 26.27 ± 4.36 | 24.23 ± 4.20<sup>a</sup> | 20.75 ± 4.39<sup>ab</sup> | 17.88 ± 5.03<sup>abc</sup> |
| SW (mmHg) | MCT-sevo | 1574±531   | 1457±751  | 1091±442<sup>ab</sup> | 848±325<sup>abc</sup> |
| ESV (ul)  | NS-sevo  | 2249±685<sup>d</sup> | 2219±653<sup>a</sup> | 1784±751<sup>ab</sup> | 1616±744<sup>abc</sup> |
|           | MCT-sevo | 60 ± 0.14   | 0.45 ± 0.13 | 0.45 ± 0.12 | 0.46 ± 0.11 |
| Ea (mmHg/ul) | NS-sevo | 0.79 ± 0.30<sup>d</sup> | 0.71 ± 0.29<sup>a</sup> | 0.72 ± 0.29<sup>a</sup> | 0.71 ± 0.27<sup>a</sup> |
|           | MCT-sevo | 2619.6 ± 702.9 | 1584.4 ± 329.4<sup>a</sup> | 1264.9 ± 147.5<sup>a</sup> | 1034.0 ± 110.5<sup>abc</sup> |
| Dp/dt max (mmHg/s) | MCT-sevo | 3359.5 ± 491.1<sup>d</sup> | 2572.6 ± 399.1<sup>a</sup> | 2194.2 ± 407.9<sup>ab</sup> | 2080.8 ± 366.8<sup>abc</sup> |
| Ees (mmHg) | NS-sevo  | 0.67±0.12 | 0.57±0.13<sup>a</sup> | 0.50±0.09<sup>ab</sup> | 0.48±0.05<sup>abc</sup> |
|           | MCT-sevo | 0.95±0.42<sup>d</sup> | 0.75±0.39<sup>a</sup> | 0.64±0.18<sup>ab</sup> | 0.58±0.16<sup>abc</sup> |
| PRSW (mmHg) | NS-sevo | 23.7±2.5 | 20.5±1.9<sup>a</sup> | 18.1±0.02<sup>a</sup> | 17.1±0.03<sup>a</sup> |
|           | MCT-sevo | 31.5±4.9<sup>d</sup> | 25.3±6.1<sup>a</sup> | 21.8±5.3<sup>a</sup> | 19.4±5.5<sup>abc</sup> |
| Dp/dt max-EDV (mmHg/s) | NS-sevo | 21.1±1.8 | 18.8±0.7<sup>a</sup> | 17.1±1.0<sup>a</sup> | 15.3±0.3<sup>abc</sup> |
|           | MCT-sevo | 41.3±9.3<sup>d</sup> | 37.9±7.6<sup>a</sup> | 33.7±8.2<sup>a</sup> | 30.3±7.0<sup>abc</sup> |
| Ees/Ea     | NS-sevo  | 1.44±0.08 | 1.30±0.03<sup>a</sup> | 1.17±0.1<sup>ab</sup> | 1.09±0.01<sup>abc</sup> |
|           | MCT-sevo | 1.42±0.33 | 1.23±0.37<sup>a</sup> | 1.11±0.35<sup>ab</sup> | 1.02±0.23<sup>abc</sup> |

Values are expressed as means±SD. group NS-sevo, n = 12; group MCT-sevo, n = 13. ESP, end-systolic pressure; EDP, end-diastolic pressure; ESV, end-systolic volume; EDV, end-diastolic volume; Dp/dt max, maximum Dp/dt; Ea, effective arterial elastance; SV, stroke volume; CO, cardiac output; EF, ejection fraction; SW, stroke work; Ees, end-systolic elastance; PRSW, preload recruitable stroke work; Dp/dt max-EDV, slope of the maximum derivative of pressure (Dp/dtmax)—end-diastolic volume (EDV) relationship; Ees/Ea, RV-pulmonary arterial (PA) coupling. P values from repeated-measures ANOVA.

<sup>a</sup> compared to T0, P<0.05;
<sup>b</sup> compared to T1, P<0.05;
<sup>c</sup> compared to T2, P<0.05;
<sup>d</sup> compared with the normal-sevo group at T0, P<0.05 from Student’s t test.

doi:10.1371/journal.pone.0154154.t002

Sevoflurane on Pulmonary Hypertension

Previous studies reported that isoflurane, sevoflurane and desflurane decrease RV contractility in a dose-related manner[12, 32]. Our study showed that sevoflurane produced dose-
dependent slight decreases of RV contractility (Ees, PRSW, and dP/dt\textsubscript{max}-EDV) in normal and PAH rats. The RV contractility, CO and EF decreased similarly after sevoflurane inhalation in both normal and PAH rats. In clinical practice, RV function in the presence of chronic PAH might be tolerant to low-concentration sevoflurane inhalation. These data indicate that sevoflurane might be suitable for sedation or as an adjunct anesthesia agent for patients with RV dysfunction.

There is growing evidence that the downregulation of SERCA2a is involved in the development of PAH and secondary RV dysfunction. The overexpression of SERCA2a has been reported to decrease pulmonary vascular remodeling, right ventricular hypertrophy and enhance cardiac contractility[33, 34]. PLB regulates the activation of SERCA2a by phosphorylation at Ser 16 and Thr 17[18]. SERCA2a/PLB interaction controls cardiac contractility, and a decrease in the SERCA2a/PLB ratio contributes to contractile dysfunction[35]. Our results showed that MCT-induced PAH is associated with downregulated SERCA2 expression, up

![Fig 3. Right ventricle (RV) pressure-volume (PV) loops. Representative recordings of RV PV loops in a normal rat (A) and a PAH rat (B) during baseline condition and a normal rat (C) and a PAH rat (D) 1.5% sevoflurane inhalation. Solid lines (black arrows) represent end-systolic pressure volume-relationship (ESPVR). RV ESP, right ventricle end-systolic pressure.](https://doi.org/10.1371/journal.pone.0154154.g003)

![Fig 4. The effects of sevoflurane on the expression of SERCA2 (A,D), PLB (B, E), SERCA2/PLB ratio (F) p-PLB(C) and p-PLB/PLB ratio(G) in the right ventricle. The results are expressed as the mean±SD, n = 3.](https://doi.org/10.1371/journal.pone.0154154.g004)
regulation of PLB, and a decreased SERCA2/PLB ratio in the RV myocardium suggesting that RV function under the condition of PAH is potentially linked to this signal pathway. An in vitro study indicated that sevoflurane depresses the contractility of isolated myocardium by affecting SERCA2a activity and intracellular Ca\(^{2+}\) homeostasis\cite{36}. Our results showed that sevoflurane increased PLB expression, decreased SERCA2 expression, and decreased the SERCA2/PLB ratio similarly in PAH group and NS group. Taken the RV function parameters together, these results may suggest that the impairment of the SR function causes a delay in SR calcium reuptake and consequently impairs lusitropic function, which might be associated with an impaired contractility index to PAH rats as well as the normal. The phosphorylation of PLB is known to be associated with enhanced critical left ventricular functions, such as contractility and relaxation. p-PLB/PLB ratio excluding the influence of the whole quantity of PLB, especially in our experiment, the changing of PLB is quit obvious, is a more objective indicators compared to sole p-PLB. Interestingly, p-PLB/PLB ratio was found significantly reduced only in PAH rats after sevoflurane administration. We speculated that sevoflurane might affect the SERCA2a activities of PAH rats through dephosphorylation of phospholamban. In normal rats, p-PLB/PLB ratio was not changed indicating this dephosphorylation modulation might be unique in PAH rats compared to normal rats. At the protein level, RV remodeling might be associated with changes both the abundance and phosphorylation levels of Ca\(^{2+}\)-handling proteins, including SERCA2a and PLB.

In conclusion, we found that sevoflurane induced a concentration-dependent depression of pulmonary, systemic hemodynamics and RV function in both normal and PAH rats. Rats with PAH can tolerate low concentration of sevoflurane (1.5%) inhalation as well as normal rats. The SERCA2-PLB signaling pathway might play a role in the pathogenesis of PAH and effects of sevoflurane on RV function. Dephosphorylation of PLB with sevoflurance may be a unique treatment target for PAH.

Supporting Information

S1 Fig. Schematic diagram depicting the experimental protocols used in the sevoflurane inhalation experiments

(TIF)

S2 Fig. Midventricular transverse sections of hearts from a normal rat (A) and a PAH rat (B). The black arrows show the RV free walls. RV wall thickness increased in the PAH rat.

(TIF)

Acknowledgments

The authors thank Wei Chao, Ph.D., M.D. in Massachusetts General Hospital, Harvard Medical School and Charles W. Buffington, M.D. in University of Pittsburgh medical center, for critical discussions on the project. And thank Jiapeng Huang, Ph.D., M.D. at Jewish Hospital, University of Louisville for review of the paper.

Author Contributions

Conceived and designed the experiments: EW. Performed the experiments: XY LW GQ HL FZ JZ. Analyzed the data: LW ZY. Contributed reagents/materials/analysis tools: HL XL. Wrote the paper: XY LW EW.
References

1. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425–1436. PMID: 1549304

2. Archer S, Rich S (2000) Primary pulmonary hypertension: a vascular biology and translational research "Work in progress". Circulation 102: 2781–2791. PMID: 11094047

3. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119: 2250–2294. doi: 10.1161/ CIRCULATIONAHA.109.192230 PMID: 19332472

4. Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ Jr. (2011) Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J Thorac Cardiovasc Surg 141: 1424–1430. doi: 10.1016/j.jtcvs.2011.02.028 PMID: 21596173

5. Ghoresi M, Evans CF, DeFilippi CR, Hobbs G, Young CA, Griffith BP, et al. (2011) Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. J Thorac Cardiovasc Surg 142: 1439–1452. doi: 10.1016/j.jtcvs. 2011.08.030 PMID: 21962906

6. Kaw R, Pasupuleti V, Deshpande A, Hamieh T, Walker E, Minaia OA (2011) Pulmonary hypertension: an important predictor of outcomes in patients undergoing non-cardiac surgery. Respir Med 105: 619–624. doi: 10.1016/j.rmed.2010.12.006 PMID: 21195595

7. Lai HC, Lai HC, Wang KY, Lee WL, Ting CT, Liu TJ (2007) Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery. Br J Anaesth 99: 184–190. PMID: 17576968

8. Menghraj SJ (2012) Anaesthetic considerations in children with congenital heart disease undergoing non-cardiac surgery. Indian J Anaesth 56: 491–495. doi: 10.4103/0019-5049.103969 PMID: 23293389

9. Friesen RH, Williams GD (2008) Anesthetic management of children with pulmonary arterial hypertension. Paediatr Anaesth 18: 208–216. doi: 10.1111/j.1460-9592.2008.02419.x PMID: 18230063

10. Riess ML, Kevin LG, McCormick J, Jiang MT, Rhodes SS, Stowe DF (2005) Anesthetic preconditioning: the role of free radicals in sevoflurane-induced attenuation of mitochondrial electron transport in Guinea pig isolated hearts. Anesth Analg 100: 46–53. PMID: 15616050

11. Wang JK, Yu LN, Zhang FJ, Yang MJ, Yu J, Yan M, et al. (2010) Postconditioning with sevoflurane protects against focal cerebral ischemia and reperfusion injury via PI3K/Akt pathway. Brain Res 1357: 142–151. doi: 10.1016/j.brainres.2010.08.009 PMID: 20705063

12. Kerbaul F, Bellezza M, Mekkaoui C, Feier H, Guidon C, Gouvernet J, et al. (2006) Sevoflurane alters right ventricular performance but not pulmonary vascular resistance in acutely instrumented anesthetized pigs. J Cardiothorac Vasc Anesth 20: 209–216. PMID: 16616661

13. Blaudszun G, Morel DR (2012) Superiority of desflurane over sevoflurane and isoflurane in the presence of pressure-overload right ventricle hypertrophy in rats. Anesthesiology 117: 1051–1061. doi: 10.1097/ALN.0b013e31826cb20b PMID: 22929732

14. Kogler H, Hartmann O, Leineweber K, Nguyen van P, Schott P, Brodde OE, et al. (2003) Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. Circ Res 93: 230–237. PMID: 12842921

15. Hardziyenka M, Campian ME, de Bruin-Bon HA, Michel MC, Tan HL (2006) Sevoflurane alters right ventricular performance but not pulmonary vascular resistance in acutely instrumented anesthetized pigs. J Cardiothorac Vasc Anesth 20: 209–216. PMID: 16616661

16. Perbet S, Bourdeaux D, Sautou V, Pereira B, Chabanne R, Constantin JM, et al. (2014) A pharmacokinetic study of 48-hour sevoflurane inhalation using a disposable delivery system (AnaConDa(R)) in ICU patients. Minerva Anestesiol 80: 655–665. PMID: 24226486
21. Boissiere J, Gautier M, Machet MC, Hanton G, Bonnet P, Eder V (2005) Doppler tissue imaging in assessment of pulmonary hypertension-induced right ventricle dysfunction. Am J Physiol Heart Circ Physiol 289: H2450–2455. PMID: 16055521
22. Kato Y, Iwase M, Kanazawa H, Kawata N, Yoshimori Y, Hashimoto K, et al. (2003) Progressive development of pulmonary hypertension leading to right ventricular hypertrophy assessed by echocardiography in rats. Exp Anim 52: 285–294. PMID: 14562804
23. Carabello BA (2002) Evolution of the study of left ventricular function: everything old is new again. Circulation 105: 2701–2703. PMID: 12057980
24. Brimioulle S, Wauthy P, Ewalenko P, Rondelet B, Vermeulen F, Kerbaul F, et al. (2003) Single-beat estimation of right ventricular end-systolic pressure-volume relationship. Am J Physiol Heart Circ Physiol 284: H1625–1630. PMID: 12531727
25. Dickstein ML, Yano O, Spotnitz HM, Burkhoff D (1995) Assessment of right ventricular contractile state with the conductance catheter technique in the pig. Cardiovasc Res 29: 820–826. PMID: 7656285
26. Faber MJ, Dalinghaus M, Lankhuizen IM, Steendijk P, Hop WC, Schoemaker RG, et al. (2006) Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loops. Am J Physiol Heart Circ Physiol 291: H1580–1586. PMID: 16679397
27. Leeuwenburgh BP, Helbing WA, Steendijk P, Schoof PH, Baan J (2001) Biventricular systolic function in young lambs subject to chronic systemic right ventricular pressure overload. Am J Physiol Heart Circ Physiol 281: H2697–2704. PMID: 11709439
28. Wauthy P, Pagnamenta A, Vassalli F, Naeije R, Brimioulle S (2004) Right ventricular adaptation to pulmonary hypertension: an interspecies comparison. Am J Physiol Heart Circ Physiol 286: H1441–1447. PMID: 14684368
29. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, et al. (1992) Effective arterial elastance as index of arterial vascular load in humans. Circulation 86: 513–521. PMID: 1638719
30. Kass DA, Kelly RP (1992) Ventriculo-arterial coupling: concepts, assumptions, and applications. Ann Biomed Eng 20: 41–62. PMID: 1562104
31. Lambermont B, Ghysen A, Kolh P, Tchana-Sato V, Segers P, Gerard P, et al. (2003) Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res 59: 412–418. PMID: 12909324
32. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, et al. (2004) Isoflurane and desflurane impair right ventricular-pulmonary arterial coupling in dogs. Anesthesiology 101: 1357–1362. PMID: 15564943
33. Bers DM (2002) Sarcoplasmic reticulum Ca release in intact ventricular myocytes. Front Biosci 7: d1697–1711. PMID: 12086924
34. Anwar A, Schluter KD, Heger J, Piper HM, Euler G (2008) Enhanced SERCA2A expression improves contractile performance of ventricular cardiomyocytes of rat under adrenergic stimulation. Pluiers Arch 457: 485–491. doi: 10.1007/s00424-008-0520-7 PMID: 18581135
35. del Monte F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ (2002) Targeting phospholamban by gene transfer in human heart failure. Circulation 105: 904–907. PMID: 11864915
36. Hannon JD, Cody MJ, Sun DX, Housmans PR (2004) Effects of isoflurane and sevoflurane on intracellular calcium and contractility in pressure-overload hypertrophy. Anesthesiology 101: 675–686. PMID: 15329592